Important Announcements

Nondiscrimination Statement Update

Boston Medical Center Health System complies with applicable Federal civil rights laws and does not discriminate on the basis of age, race, color, national origin (including limited English proficiency and primary language), religion, culture, physical or mental disabilities, socioeconomic status, sex, sexual orientation and gender identity and/or expression. BMCHS provides free aids and services to people with disabilities and free language services to people whose primary language is not English.

To see our full nondiscrimination statement, click here.

Campus Construction Update

Starting September 14, we’re closing the Menino building lobby entrance. This, along with the ongoing Yawkey building entrance closure, will help us bring you an even better campus experience that matches the exceptional care you've come to expect. Please enter the Menino and Yawkey buildings through the Moakley building, and make sure to leave extra time to get to your appointment. Thank you for your patience. 

Click here to learn more about our campus redesign. 

placental biologyOur multidisciplinary program examines several aspects of how placental biology that can influence fetal physiology. This program includes the following key studies: evaluation of the effects of prenatal exposure to opioids on the placenta including DNA methylation and gene expression, examination of COVID-19 biology during pregnancy and analysis of how placental disorders impact development to increase the risk of neonatal lung and gut disorders.

See all of our Pediatric Research programs.

Contact

Principal Investigator 
Elizabeth Taglauer 
Elizabeth.Taglauer@bmc.org

Research projects

  • “MOM NEST” Study: Safety, Efficacy, Pharmacokinetics, and Pharmacogenomics of Naltrexone in Pregnant Women with Opioid Use Disorder (R01 HD96798), NCT03718104
  • Effects of Prenatal Opioid Exposure on Placental DNA Methylation and Gene Expression, March of Dimes Research Grant
  • “MASC” Study: Mothers and Infants Affected by Signs and Symptoms of COVID-19, BU CTSI
  • “AliGN” Study: Antenatal determinants of Lung and Gut disease in Neonates
  • “PRIME” Study: Placental Repository to Improve Infant Outcomes